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Abstract
Background: Melanoma is the leading cause of 80% of skin cancer worldwide due to its high proliferation rate, metastatic nature,
and limited effective therapies. Given the rapid increase in its incidence compared to other skin cancers, new therapeutic agents are
needed to control the disease. Scientists are interested in medicinal plants due to their anticancer properties. The rhizomes of the
Iris germanica L., known as “Irsa”, is one of the herbs used in traditional Persian medicine for the treatment of various skin cancers.
Objectives: This study aimed at investigating the cytotoxic effects of Iris germanicaon A375 melanoma and AGO-1522 normal human
fibroblast cell lines for the first time.
Methods: The ethanolic extract was prepared by the maceration method. Cell viability and cytotoxic activities were assessed
through 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and flow cytometric assay, using annexin V/propidium
iodide (PI) staining.
Results: IC50 values were estimated for the A375 melanoma and the AGO-1522 normal cell lines. We revealed that the IC50 for the
A375 melanoma was 0.0438 mg/mL and for the AGO-1522 normal cell line was 0.8494 mg/mL after 48 hours of treatment. Further-
more, flow cytometry analysis illustrated that 0.125 mg/mL of the Iris germanica extract could lead to 55.24% apoptosis of the A375
melanoma cell line. The same concentration of the Iris germanica extracts only lead to 8.76% apoptosis in the AGO-1522 cell line.
Conclusions: Iris germanica extract has considerable cytotoxic effects on the human melanoma cell line. Further studies are re-
quired to demonstrate the therapeutic effects of Iris germanica on melanoma cancer.
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1. Background
Melanoma is a malignant tumor of the skin that is
originated from melanocyte cells. Cells become prolifer-
ative, dysplastic, expand from epidermis to dermis, and
can quickly metastasize to other organs (1). The prevalence
of melanoma varies in different geographical regions and
between races. The global incidence of melanoma has in-
creased rapidly in recent decades and its prevalence is dou-
bled every 10 to 20 years (2, 3).
Human skin melanoma is one of the most severe skin
cancers and has a high prevalence and mortality rate. Cur-
rently, in the United States, melanoma is the 5th most com-
mon cancer in men and the 6th most common cancer in
women (4), which is estimated to be even higher due to the
lack of proper diagnostic criteria (5).
Melanoma has various risk factors including exposure
to sunshine, genetic and epigenetic factors, immunosup-
pression, multiple and abnormal nevi, as well as occupa-
tional and nutritional factors (6-9). The most potent risk
factor is exposure to type B ultraviolet radiation (UVB),
while type A (UVA) such as tanning and psoralen plus
ultraviolet A (PUVA) therapy can increase the chance of
melanoma (10).
Many efforts have been made to achieve effective ther-
apies for the disease. Common therapies are surgery,
chemotherapy, hormone therapy, radiation therapy, gene
therapy, and immunotherapy. Treatment for local lesions
in the early stage is surgery, while in advanced cases, re-
sponse to treatment is weak because they are metastatic
and resistant to common medications such as single-
drug chemotherapy regimens and radiotherapy, suggest-
ing novel, effective, and low-risk therapies (11).
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The use of medicinal plants for cancer treatment has
always been an option for researchers (12, 13). Iranian sci-
entists have provided different natural therapies for mod-
ulating cancers in traditional Persian medicine (14). Iris ger-
manicaL., known as “Irsa” in Persian medicine, is a herb and
its rhizome has been used for the treatment of a skin can-
cer similar to melanoma (15-17).
The plant is a member of the Iridaceae family and has
many varieties. This plant is popular in many parts of the
world including Iran (18). The rhizome of Iris germanica
is a rich source of flavonoids such as irigenin, nigricin,
irilone, and irisolidone (19-21). Benzene derivatives have
also been obtained from the methanolic extract of the Irsa
rhizomes (22). The fresh rhizome of Irsa contains triter-
penoids called “iridals”, which are the precursor of iron.
Irones are also extracted from the dried rhizome of Irsa
and used for medical and perfumery purposes (23). In ad-
dition to these compounds, various types of sterols includ-
ing sitosterol and stigmasterol have been extracted from
the Irsa rhizomes (24). Furthermore, antioxidant, anti-
inflammatory, anti-bacterial, and anti-ulcer properties of
Irsa compounds have been investigated in several studies
(18, 21, 25).
2. Objectives
Previous studies have demonstrated anti-mutagenic,
anti-proliferative, and cytotoxic effects of the Irsa extract
in different cancer cell lines (16, 25-27), while no studies
have been performed so far on the impact of the whole ex-
tract of Irsa on A375 (human skin melanoma) cancer cell
line. In this study with the inspiration of traditional Per-
sian medicine, the effect of Irsa extract on proliferation
and apoptosis of the A375 melanoma (cancer) cell line was
investigated for the first time and compared with the AGO-
1522 (normal human fibroblast) cell line.
3. Methods
3.1. Preparation of Plant Sample
The complete plant of Iris germanica with blue flowers
and the Herbariums registration number of S-A1037-131 in
the Plant Extract Bank was obtained from Karaj, Iran. The
plant is also called "Susan Assemanjooni" according to the
traditional and allopathic medicine references and used af-
ter confirmation by the Herbal Medicines Department of
the Pharmacy, Shahid Beheshti University of Medical Sci-
ences, Tehran, Iran. The rhizome was separated from the
rest of the plant, dried in shadow, chopped, and kept in a
cold place until extraction.
3.2. Extraction and Condensation
Two hundred grams of the chopped rhizome was
added into a mixture of water (480 mL) and (120 mL
ethanol) for 72 hours. Extraction of the chopped rhizome
by ethanol has the lowest damage to compounds such as al-
kaloids, saponins, carbohydrates, tannins, and flavonoids
(28, 29). Next, the extract was filtered with a Whatman fil-
ter paper No. 1, incubated in a 70°C water bath for 12 hours,
concentrated, and dried. The extract was stored in a refrig-
erator at 4°C for subsequent molecular experiments.
3.3. A375 and AGO-1522 Cell Lines
The A375 human melanoma cell line (C10141 IBRC, Iran)
is originated from a 54-year-old woman with malignant
melanoma in 1973.
The AGO-1522 cell line, which is a normal human fibrob-
last cell line, was used as a healthy control cell line. The
cells were taken from the skin of a 3-day-old (male) new-
born.
3.4. Cell Culture
A375 and AGO-1522 cell lines were cultured in RPMI-
1640 medium supplemented with 10% fetal bovine serum
(FBS).
Cells (104 cells) were cultured in each well of a 96-well
plate with 100 µL of culture medium. In the next step, the
plant extract was dissolved in dimethyl sulfoxide (DMSO)
and cells were treated with different concentrations (0.031,
0.0625, 0.125, 0.25, 0.5, and 1 mg/mL). Then, cells were incu-
bated in an incubator with 37°C, 5% CO2, and humidified
atmosphere for 48 hours.
In addition to the Irsa extract, the A375 and AGO-1522
cell lines were treated with 100, 250, 500, 750, and 1000
µM concentrations of dacarbazine (Sigma Chemical Co., St.
Louis, MO, USA) as a chemotherapeutic agent and positive
control. In previous studies, a range of 100 to 1000µM was
used for cytotoxicity (30, 31).
3.5. MTT Assay
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) was prepared at a concentration of 5
mg in a serum-free RPMI medium. The supernatant of
cell lines was removed and incubated with the different
concentrations of the Iris extract in the 96-well plate.
Then, the MTT solution was diluted with serum-free RPMI
with a 1:1 ratio, and 100 µL of the obtained solution was
added to each well of the plate and incubated at 37°C for 3
hours. Then, the solution was removed, and 100µL of 0.04
HCl-containing acidic isopropanol was added. After the
appearance of the violet color of formazan crystals, the
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plates were read at 570 nm wavelength, using an enzyme-
linked immunosorbent assay (ELISA) reader (BioTek ELISA
reader, USA).
3.6. Flow Cytometry Analysis
Flow cytometry was performed to evaluate the viabil-
ity of cells treated with 0.015, 0.0625, and 0.031 mg/mL
concentrations of the Irsa extract. 1000 µM dacarbazine
and 0.5% DMSO were used as positive and negative con-
trols, respectively. Flow cytometry was carried out accord-
ing to the BD kit instruction. Briefly, the supernatants of
wells treated with the Irsa extract and dacarbazine were re-
moved, and cells were isolated, using trypsin. Then, the cell
suspension was divided into four 1.5 mL microtubes and
centrifuged at 1500 rpm for 5 minutes. After removing the
supernatant, 100 µL binding buffer was added to the cells.
Five microliter Annexin V was added to 2 microtubes and
incubated for 15 minutes; then, 5 µL propidium iodide (PI)
was added to one of the two microtubes. Five microliter PI
was added to one of the two primary microtubes that only
had the binding buffer, and the other microtube remained
intact. All microtubes were incubated for 2 minutes and,
then, read by flow cytometry (BD FACSCalibur flow cytome-
ter, USA). In addition to dacarbazine and Irsa extract, 0.5%
DMSO was used as a negative control.
3.7. Statistical Analysis
Each MTT assay was performed with 8 repetitions. The
growth curve was also obtained, using the equation of the
concentration regression line. The cell growth rate was cal-








Finally, IC50 (the drug concentration that destroys 50%
of the cells) was obtained by using the plotted curve. In-
deed, IC50 was used to quantify the measure that indicates
how much of the Irsa extract is needed to apoptosis the
cells by 50%. The effects of different levels of dacarbazine
and Irsa extract on A375 and AGO-1522 cell lines were com-
pared with one-way ANOVA, using SPSS release 25.0 (SPSS
Inc., Chicago, IL, USA). P-values of < 0.05 were considered
significant.
4. Results
4.1. MTT Assay on A375 Melanoma and AGO-1522 Control Cell
Lines
According to the MTT assay, control and melanoma
cancer cell lines had different sensitivities to the various
concentrations of dacarbazine and Iris extract. The viabil-
ity of the cells was evaluated, using MTT. The maximum
inhibitory concentration (IC50) of the Irsa extract for A375
melanoma cells was 0.0438 mg/mL after 48 hours of treat-
ment. At the mentioned concentration, 50% of the cells in
the plate lost their proliferation and viability. In addition,
IC50 of the Irsa extract for the AGO-1522 control cell line
was 0.8449 mg/mL and about 50% of the cultured cells lost
their viability (Figure 1 and Table 1). Therefore, melanoma
cancer cells were destroyed at 0.0438 mg/mL of Irsa extract,
while the viability of control cells was not affected.
Table 1. IC50 Values of Iris germanica L. on AGO-1522 (Normal) and A375 (Melanoma)
Cell Lines a





a MTT assay of 1000 µM of dacarbazine on the cell lines showed the highest
toxicity. Therefore, this concentration was used as the positive control.
4.2. FlowCytometry of Irsa Extract onA375MelanomaandAGO-
1522 Control Cell Lines
The viability of the AGO-1522 cells in 0.125 mg/mL of
Irsa extract was similar to the negative control. There-
fore, the 0.125 mg/mL concentration of Irsa extract was the
most suitable recommended concentration with a low cy-
totoxic effect on the AGO-1522 cells (Figure 2). However, 0.25
mg/mL and 0.5 mg/mL concentrations of the extract led to
77.88% and 70.7% of apoptosis in the AGO-1522 cell line, re-
spectively.
According to our results, 0.125 mg/mL of Irsa extract
lead to 96.7% apoptosis in the A375 melanoma cell line,
whereas the same concentration had the most viability
and the least apoptosis rate (24.33%) in the AGO-1522 cell
line (Figure 3 and Table 2).
Besides, the viability of the AGO-1522 control cells and
the A375 melanoma cells treated with 1000 µM of dacar-
bazine were 18.4% and 8.53%, respectively. Moreover, the
viability of the AGO-1522 control cell line and the A375
melanoma cell line treated with the 0.125 mg/mL of the Irsa
extract was 72.1% and 2.87%, respectively (Figure 4).
4.3. Statistical Findings
Statistical analysis with ANOVA test showed a signifi-
cant difference in growth inhibition of cancer cells treated
with different levels of Iris extract (P < 0.001). In addition,
there was a significant difference in growth inhibition of
the AGO-1522 cell line treated with various levels of Irsa ex-
tract (P < 0.001).
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Figure 1. Measurement of IC50 values of Irsa extract on A375 melanoma cell line and AGO-1522 control cell line.
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Figure 2. Flow cytometric analysis and comparison between the 0.125 mg/mL with zero concentration (negative control) of the Irsa extract in AGO-1522 cells. At the 0.125
mg/mL of Irsa extract, the viability of the cells was similar to the negative control. Therefore, the 0.125 mg/mL of Irsa extract is the most suitable recommended concentration
that has a lower cytotoxic effect on AGO-1522 cells.
4 Int J Cancer Manag. 2021; 14(6):e111319.






































FL3-H:: TEST-PI FL3-H:: TEST-PI
0 1
10 10 10 10 10
2 3 4 0 1


















Figure 3. A. In the 0.125 mg/mL of Irsa extract on the A375 melanoma cell line, 96.7% of the cells were apoptotic. B. However, this rate was 24.33% for the AGO-1522 cell line.
Table 2. Evaluation of the Different Concentrations of the Irsa Extract on Apoptosis Induction in A375 Melanoma Cells and AGO-1522 Healthy Cells
Category
Treated Cells
Non-treated (DMSO) (Control -) Dacarbazine (Control-+)
0.031 mg/mL 0.0625 mg/mL 0.125 mg/mL 0.125 mg/mL 0.25 mg/mL 0.5 mg/mL
Cell Type A375 A375 A375 AGO-1522 AGO-1522 AGO-1522 A375 AGO-1522 A375 AGO-1522
Apoptotic
Cells
5.51 48.45 55.24 8.76 11.06 48.9 4.26 8.72 91.2 77.9
Live Cells 83.9 3.11 2.87 72.1 19.9 18 84.8 71.9 8.53 18.4
Necrosis 10.6 48.4 41.8 19.2 69 33.1 10.9 18.7 0.230 3.75
Moreover, a significant difference was observed be-
tween the inhibitory effects of Irsa extract on induction of
apoptosis in the A375 cell line compared to the AGO-1522
cell line (P < 0.001).
5. Discussion
Melanoma is one of the most common and malignant
forms of skin cancer that originates from melanocyte cells.
Melanocytes are pigment-including skin cells that produce
pigment in response to irritations such as UV radiation.
These cells are responsible for the color of skin, eyes, and
hair. Environmental and genetic factors are involved in
their development (32).
According to the World Health Organization (WHO),
the incidence of melanoma is rapidly increasing in com-
parison to other skin cancers (33). The conventional
treatments for melanoma including immunotherapy,
chemotherapy, radiotherapy, and surgery did not show
promising results and had their limitations (34). Re-
cently, few effective treatments have been developed
including immunotherapy with interferon (IFN) alfa-2b,
interleukin (IL)-2, anti-CTLA-4, ipilimumab, and BRAF and
MEK inhibitors. These treatments had many side effects,
long-term responses, and were cost-effective (35-37). Due
to these problems, alternative therapies are highly wel-
comed in this field (38). In the present study, Iris germanica
L., known as Irsa, was selected to achieve an effective and
less toxic treatment for melanoma.
In 2016, scientists at the Applied Medical Center of Ko-
rea showed that the ethanolic extract of Gardenia jasmi-
noides Ellis roasted fruit inhibited migration of metastatic
melanoma pulmonary tumor cells and reduced angiogen-
esis (39). In another study, herbal medicine from the gin-
seng family (Ginsenoside Rg3) was introduced to the sci-
entific community as a unique product for the treatment
of melanoma. This herbal medicine was able to inhibit
mediators involved in tumor growth such as fucosyltrans-
ferase IV (FUT4) and induced apoptosis in a melanoma cell
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Figure 4. The effect of 1000 µM treatment with dacarbazine on the induction of apoptosis in A375 melanoma (A.) and AGO-1522 control (B.) cell lines. The rate of apoptotic
cells to living cells was 91.2% to 8.53% and 77.9% to 14.4%, respectively.
line (40). Furthermore, Chinese scientists identified the
molecular mechanisms implicated in cell cytotoxicity of
the Physalin A on the A375-S2 human melanoma cell line.
This compound is an active withanolide that is derived
from the physalis alkekengi L. and the Makino shrub called
Jin Deng Long in Chinese traditional herbal medicine. The
cytotoxic effect of the Jin Deng Long on the melanoma cell
line has been investigated in previous studies (41). In re-
cent years, Chinese researchers have also investigated the
cytotoxic effect and anti-tumor mechanism of Chinese tra-
ditional herbs and their derivatives on melanoma and pul-
monary metastatic melanoma (42-45).
None of the studies have investigated the cytotoxic-
ity effect of the herbs extract on the A375 cell line; there-
fore, no comparison can be performed with the current
study. However, the cytotoxic effects of certain compounds
of the Irsa extract on different cancer cell lines other than
melanoma have been investigated in previous studies.
The protective effects of isoflavonoids of the Irsa rhi-
zome extract on the inflammatory condition of the Hepa-
1c1c7 cell line were evaluated. It was revealed that the com-
pounds present in the Irsa extract could inhibit the activ-
ity of cytochrome P450 1A. In addition, isoflavone 2, 3, and 5
can induce NAD(P)H quinone reductase activity. The effects
of Irsa on cancer cells are exerted through the activation
of anti-inflammatory mechanisms (46). The anticancer ef-
fects of isoflavonoids of the Irsa extract on the EAC cancer
cell line have also been studied, and the results showed
that this product could inhibit the proliferation of the can-
cer cells (25).
In another study, the therapeutic effects of lipid com-
pounds of the Irsa extract on the Hela cancer cell line were
investigated. The study showed that the Irsa extract could
inhibit migration of the cells and maintain cells in the G1
phase of the cell cycle. The Irsa extract prevents the migra-
tion of cancer cells by increasing adhesion molecules and
producing more actin fibers (47).
The superiority of triterpenoids of the Irsa extract to
doxorubicin was demonstrated in the A2780 and K562 can-
cer cell lines. Although these cell lines are resistant to a
large number of chemotherapy drugs, they respond prop-
erly and showed cytotoxicity against the Irsa extract (48).
So far, no studies have been carried out to evaluate the
Irsa extract therapeutic effects on the A375 melanoma cell
line. Our study was performed for the first time to study
the effects of the total Irsa extract on proliferation and
apoptosis in the A375 melanoma cell line compared these
effects with the AGO-1522 as a control cell line.
According to the present study, 0.0438 mg/mL of the
Irsa extract destroys 50% of the A375 melanoma cell line,
while no significant destructive effect on proliferation and
viability of the AGO-1522 cell line was not observed.
Based on the flow cytometry results, the Irsa extract,
similar to dacarbazine, lead to apoptosis in the melanoma
cancer cells. Nonetheless, the Irsa extract, unlike dacar-
bazine, had no cytotoxic effect on normal cells. In addition,
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flow cytometry results showed that 0.125 mg/mL of Irsa ex-
tract had the most cytotoxic effect on the A375 cell line and
the highest rate of apoptotic and necrotized cells were ob-
served. According to the results, the best-recommended
concentration for A375 melanoma and AGO-1522 control
cell lines is 0.125 mg/mL of the Irsa extract. This concentra-
tion not only had the highest cytotoxic effects on the A375
melanoma cell line but also had the lowest cytotoxic effects
on the AGO-1522 control cell line.
5.1. Conclusions
We evaluated cytotoxic effects and apoptosis induc-
tion of the Iris germanica L. total extract on the human
skin melanoma cell line (A375) for the first time. Our re-
sults showed that 0.125 mg/mL of the Irsa extract signifi-
cantly increase apoptosis in melanoma cancer cells, while
it was entirely safe for the normal cell lines. Therefore, this
compound can be considered a novel, side-effect-free treat-
ment for human skin melanoma.
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